# Alexander J. Stratigos

Source: https://onco.cc/people/alexander-stratigos/  
OnCo record `alexander-stratigos` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Athens dermatologist who led the trial showing that cemiplimab works in advanced basal cell carcinoma after Hedgehog inhibitors have failed, and who co-authors the European skin cancer guidelines.

## Summary

Alexander Stratigos is professor of dermatology at the University of Athens and works at Andreas Sygros Hospital. He was first author of the 2021 Lancet Oncology report of the phase 2 trial in which the PD-1 antibody cemiplimab produced durable responses in locally advanced basal cell carcinoma after progression on or intolerance of Hedgehog pathway inhibitors, leading to its approval in that setting. He leads the European guideline groups for basal and squamous-cell skin cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: skin; immunotherapy; guidelines
- Role: Professor of Dermatology, National and Kapodistrian University of Athens, Andreas Sygros Hospital
- Specialisms: Basal cell carcinoma; Cutaneous squamous-cell carcinoma; Skin cancer guidelines

## Connected records

- cancers: [Advanced cutaneous squamous cell carcinoma](https://onco.cc/cancers/advanced-cutaneous-scc/), [Locally advanced and metastatic basal cell carcinoma](https://onco.cc/cancers/locally-advanced-bcc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- institutions: [National and Kapodistrian University of Athens, School of Medicine](https://onco.cc/institutions/nkua-athens/)
- key papers: [Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy](https://onco.cc/key-papers/paper-cemiplimab-bcc-stratigos-lancet-oncol-2021/)

---
JSON: https://onco.cc/api/v1/entities/alexander-stratigos.json